(IN BRIEF) Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant. The approval is based on positive results from … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Approval, cancer treatment, CHINA, clinical trials, EU, FDA, global health, IMROZ study, isatuximab, Japan, Multiple Myeloma, Multiple Myeloma Treatment, new approvals, NMPA, oncology, Sanofi, Sarclisa, transplant-ineligible, VRd
(IN BRIEF) UZ Leuven has secured a €230 million loan from the European Investment Bank (EIB) to support its expansion and modernization efforts as part of its “Health Sciences Campus 2.0” masterplan. The funding will be used to upgrade critical … Read the full press release
Posted in Banks, Belgium, Business, Economy, Environment, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Luxembourg, Management, News, Science, Technology
Tagged ambulatory care, EIB, European Investment Bank, Flanders, Health Sciences Campus 2.0, innovation ecosystem, Intensive Care Units, knowledge economy, KU Leuven, nuclear medicine, oncology, operating theatres, partnership, patient care, Paul Herijgers, Pellenberg campus, research facilities, research infrastructure, Robert de Groot, social infrastructure, sustainability, UZ Leuven, VIPA, €230 million loan
(IN BRIEF) Sanofi’s Sarclisa has been approved by the European Union as the first anti-CD38 therapy in combination with VRd to treat adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This approval is … Read the full press release
Posted in Business, European Union, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged CD38 monoclonal antibody, clinical development, clinical trials, European Union approval, FDA approval, hematologic malignancies, immunoscience, isatuximab, Multiple Myeloma, NDMM, oncology, orphan drug exclusivity, Sanofi, Sarclisa, transplant-ineligible, treatment breakthrough, VRd
(IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation. The approval is based on … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged acalabrutinib, AstraZeneca, autologous hematopoietic stem cell transplantation, bendamustine, blood cancers, Bruton’s tyrosine kinase, BTK inhibitor, Calquence, chemoimmunotherapy, COVID-19, Dave Fredrickson, ECHO Phase III trial, FDA, global regulatory review, international markets, Lymphoma Research Foundation, mantle cell lymphoma, MCL, Meghan Gutierrez, Michael Wang, oncology, PFS, progression-free survival, Project Orbis, regulatory submission, rituximab, safety profile, U.S. approval
(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan has been accepted by the U.S. FDA for treating advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in patients who have previously received systemic therapies. The … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged advanced NSCLC, antibody-drug conjugate, AstraZeneca, Biologics License Application, BLA, breakthrough therapy designation, Daiichi Sankyo, datopotamab deruxtecan, drug approval, EGFR-mutated, EGFR-tyrosine kinase inhibitors, FDA, metastatic NSCLC, non-small cell lung cancer, NSCLC, objective response rate, oncology, partnership, Phase III Trials, Priority Review, safety profile, systemic therapies, TROP2-directed, TROPION-Lung01, TROPION-Lung05, TROPION-Lung14, TROPION-Lung15
(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). Scemblix achieved significantly higher major … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged 96-week results, asciminib, ASH Annual Meeting, chronic myeloid leukemia, CML care, discontinuation rate, imatinib, major molecular response, MMR, National Comprehensive Cancer Network, NCCN, newly diagnosed settings, Novartis, oncology, Ph+ CML-CP, Phase II ASC2ESCALATE trial, Phase III ASC4FIRST trial, Philadelphia chromosome-positive chronic myeloid leukemia, safety, Scemblix, Second-Line Treatment, severe adverse events, standard-of-care, TKIs, tolerability, tyrosine kinase inhibitors
(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release
Posted in Finland, Germany, Healthcare, Insurance, News, Pharma & Biotech, Science, Society, Switzerland, Technology, United Kingdom
Tagged accessible cancer solutions, AstraZeneca, Aviva, BioNTech, breast cancer, breast cancer screening, cancer care, cancer diagnostics, cancer prevention awareness, cancer research, cancer treatment, colorectal cancer, Daiichi Sankyo, datopotamab deruxtecan, Duality Biologics, Eckert & Ziegler, EMA, FDA, genetic risk information, Inspirna, lung cancer, Merck KGaA, multi-cancer early detection, neuroendocrine neoplasms diagnostics, Novartis, ompenaclid, oncology, polygenic risk score, preventive healthcare, Professor Tim Maughan, ReSisTrace methodology, Stage III EGFR-mutated lung cancer, Swiss Re Institute, Tagrisso, treatment-resistant cancer cells, University of Helsinki, University of Liverpool
(IN BRIEF) AstraZeneca has entered into a collaboration and investment agreement with biotech firm Cellectis to fast-track the development of cutting-edge therapeutics in areas such as oncology, immunology, and rare diseases. This partnership will leverage Cellectis’ gene editing technologies and … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adrian Kemp, André Choulika, AstraZeneca, Cellectis, gene therapy, immunology, Marc Dunoyer, oncology, partnership, rare diseases, sustainability
(IN BRIEF) Merck, a prominent science and technology company, has entered into a strategic partnership with Jiangsu Hengrui Pharmaceuticals. This collaboration includes an exclusive global license (excluding China) to develop and commercialize Hengrui’s advanced PARP1 inhibitor, HRS-1167. Additionally, there is … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Tagged ADC, antibody-drug conjugate, ATM, ATR, Cancer, CEACAM5-targeting ADC, Claudin-18.2, Danny Bar-Zohar, DDR cascade, DNA-PK, Frank Jiang, Hengrui, HRS-1167, inhibitor, Jiangsu Hengrui Pharmaceuticals Co. Ltd., M9140, Merck, metastatic colorectal cancer, oncology, PARP, PARP1, poly (ADP-ribose) polymerase 1, SHR-A1904
(IN BRIEF) Servier, a global pharmaceutical group, has partnered with Owkin, a biotech company specializing in AI-driven drug discovery and diagnostics, to accelerate the development of better-targeted therapies in various disease areas, including oncology. The collaboration aims to leverage AI … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Environment, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged AI, Claude Bertrand, Disease Treatment, INNOVATION, oncology, Owkin, partnership, Servier, sustainability, therapies, Thomas Clozel
(IN BRIEF) Merck, a leading science and technology company, is set to present 28 abstracts at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting in Madrid. These abstracts will showcase the latest research on Merck’s oncology portfolio, addressing … Read the full press release
Posted in Business, Germany, Healthcare, Management, Media, News, Pharma & Biotech, Science, Spain, Technology
Tagged BAVENCIO™, bladder, cancer treatment, colorectal, ERBITUX, ESMO 2023, head and neck, lung, Madrid, Merck, oncology, TEPMETKO, Xevinapant
(IN BRIEF) Merck, a prominent science and technology company, has announced strategic drug discovery collaborations with AI technology firms BenevolentAI and Exscientia. These partnerships aim to leverage AI-driven design and discovery capabilities to advance research efforts in key therapeutic areas, … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI, AI-Driven Drug, BenevolentAI, Danny Bar-Zohar, data, Exscientia, immunology, Merck, Neurology, oncology, partnership, science
(IN BRIEF) AstraZeneca will showcase new data from its industry-leading Oncology pipeline and portfolio at the American Association for Cancer Research Annual Meeting. A total of 70 presentations will be given, including a plenary presentation on the AEGEAN Phase III … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged AstraZeneca, AZD5335, AZD9592, early-stage, Imfinzi, lung cancer, oncology, Susan Galbraith, treatment
(PRESS RELEASE) SANOFI, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced an exclusive worldwide collaboration agreement signed with IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and … Read the full press release
Tony Wood to assume full accountability for GSK R&D in August 2022 Hal Barron to transition in August 2022 from CSO to a GSK Non-Executive Director with additional responsibilities to support R&D (PRESS RELEASE) LONDON, 19-Jan-2022 — /EuropaWire/ — GlaxoSmithKline … Read the full press release
Posted in Artificial Intelligence (AI), Healthcare, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academy of Medical Sciences, Adrestia, Altius Institute, Altos Labs, appointment, artificial-intelligence, biotechnology, Blenrep, Board of the Rosalind Franklin Institute, Cabenuva, Chief Scientific Officer, CSO, Dr. Hal Barron, Emma Walmsley, Genome Research, genomics, GlaxoSmithKline plc, GSK, immunology, Imperial College, infectious disease, Jemperli, Machine Learning, medicines, Nucala®, oncology, Pfizer, R&D, research and development, Royal Society of Biology, Royal Society of Chemistry, Tony Wood, UK National Genomics Board, University of Newcastle, Xevudy
Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days The secondary … Read the full press release
EQT Infrastructure has agreed to acquire Icon Group from a consortium including Goldman Sachs Asset Management, QIC and Pagoda. Goldman Sachs Asset Management will remain a minority shareholder as part of the transaction Icon Group is Australia’s largest vertically integrated cancer … Read the full press release
Posted in Business, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Sweden, Technology
Tagged acquisition, Australia, Blikk, cancer care, cancer clinical trials, cancer drug infusions, cancer patients, cancer treatment, compounding, decentralisation, Deloitte, diagnostic imaging provider, digitalization, EQT, EQT Infrastructure, EQT Infrastructure V, Goldman Sachs Asset Management, healthcare sector, Herbert Smith Freehills, I-MED, Icon Group, integrated cancer-care operator, Integrated Clinical Oncology Network, investment, Jim Kelly, Ken Wong, Mark Middleton, medical oncology, Meine Radiologie Holding, Morgan Stanley, nuclear medicine, oncology, Pagoda Investment Advisors, pharmacy, PwC, QIC Private Capital Pty Ltd, Radiation Oncology, radiology, radiotherapy, Stephanie Hui
(PRESS RELEASE) BERLIN, 26-Jul-2021 — /EuropaWire/ — Bayer, a global enterprise with core competencies in the life science fields of health care and nutrition, has announced that Prof. Dr. Dominik Ruettinger has been appointed as the new Head of Research … Read the full press release
Posted in Germany, Healthcare, Management, News, Pharma & Biotech, Technology
Tagged Amgen Inc., Bayer AG, Biomarker Development, Blinatumumab, Blincyto, Dominik Ruettinger, Dr. Christian Rommel, Early Clinical, Micromet Inc., oncology, pharmaceuticals, pRED, Prof. Dr. Dominik Ruettinger, RESEARCH, Roche, Surgical Oncology, therapeutic development, translational clinical research, tumor, tumor immunology, University of Munich
Financing deal worth €15.0 million signed to support clinical development programme for masitinib Masitinib developed as a credible candidate for treating COVID-19 in addition to other diseases for which no therapeutic solutions are available (PRESS RELEASE) PARIS, 30-Nov-2020 — /EuropaWire/ — … Read the full press release
Posted in Banks, European Union, Financial, France, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Small Business
Tagged 3CL protease, AB Science SA, Alain Moussy, Ambroise Fayolle, anti-inflammatory, antiviral, chemotherapy, COVID-19, COVID-19 treatment, EIB, European Commission, European Fund for Strategic Investments, European Investment Bank, European Union, financing, health crisis, Horizon 2020, immunotherapeutic, inflammatory disease, innovationm, InnovFin, investments, kinase inhibitors, kinases, loan, macrophages, masitinib, microglia, neurological diseases, oncology, PKIs, RESEARCH, SARS-CoV-2, tyrosine kinase inhibitor
(PRESS RELEASE) CAMBRIDGE, 20-Nov-2020 — /EuropaWire/ — AstraZeneca (LON: AZN), a global, science-led biopharmaceutical company, has announced the US Food and Drug Administration (FDA) approval of its Imfinzi (durvalumab) for an additional dosing option, a 1,500mg fixed dose every four … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged bladder cancer, Dave Fredrickson, Imfinzi, Io, lung cancer, NSCLC, oncology, SCLC, Small cell lung cancer, Victoria M. Villaflor MD
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?